AKT1 and melanoma: PFKFB4, which confers anabolic flexibility by preferentially re-directing glucose to the pentose phosphate pathway [85,86] and enhances melanoma cell migration through RAS/AKT-dependent signaling independent of glycolysis [87], was also downregulated at the mRNA level after omacetaxine but not palbociclib treatment (Figure 7B).